

**Leroy A. Richardson,**  
*Chief, Information Collection Review Office,  
 Office of Scientific Integrity, Office of the  
 Associate Director for Science, Office of the  
 Director, Centers for Disease Control and  
 Prevention.*

[FR Doc. 2014-21379 Filed 9-8-14; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND  
 HUMAN SERVICES**

**Centers for Disease Control and  
 Prevention**

**Georgia Tuberculosis Outbreak Among  
 Homeless**

**AGENCY:** Centers for Disease Control and  
 Prevention (CDC), Department of Health  
 and Human Services (HHS).

**ACTION:** Notice of award.

**SUMMARY:** The Centers for Disease  
 Control and Prevention (CDC) located  
 within the United States Department of  
 Health and Human Services (HHS)  
 announces a notice of award to the  
 Georgia Department of Public Health,  
 Tuberculosis (TB) Program. This award  
 will be in the amount of \$419,095.00.

The purpose of this award is to halt  
 the further spread of a drug-resistant  
 strain of tuberculosis associated with  
 multiple homeless shelters in Fulton  
 County, Georgia.

**DATES:** It is expected the notice of award  
 will begin on or about September 3,  
 2014. The project period will be for one  
 year.

**FOR FURTHER INFORMATION CONTACT:** Gail  
 Burns-Grant, Division of Tuberculosis  
 Elimination, Field Services and  
 Evaluation Branch, Centers for Disease  
 Control and Prevention, 1600 Clifton  
 Road NE., MS E-10, Atlanta, GA 30333;  
 phone: 404-639-5344; email: *GAB2@  
 cdc.gov*.

**SUPPLEMENTARY INFORMATION:** Currently,  
 the state of Georgia is experiencing a  
 public health emergency in Fulton  
 County where there has been extensive  
 transmission of a drug-resistant strain of  
 tuberculosis (TB) associated with  
 multiple homeless shelters in the  
 county. The Georgia Department of  
 Public Health asked CDC to provide  
 emergency funding for the immediate  
 implementation of CDC  
 recommendations provided as a result  
 of a May 2014 outbreak investigation to  
 prevent further transmission of this  
 drug-resistant strain of tuberculosis and  
 to prevent further deaths associated  
 with this outbreak. Project number is  
 CDC-RFA-PS14-1416.

Dated: September 4, 2014.

**Ron A. Otten,**  
*Acting Deputy Associate Director for Science,  
 Centers for Disease Control and Prevention.*

[FR Doc. 2014-21455 Filed 9-4-14; 4:15 pm]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND  
 HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA-2014-N-0001]

**Advisory Committee Renewals;  
 Correction**

**AGENCY:** Food and Drug Administration,  
 HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug  
 Administration (FDA) is correcting a  
 notice entitled “Advisory Committee  
 Renewals” that appeared in the **Federal  
 Register** of August 25, 2014 (79 FR  
 50658). The document announced the  
 renewal of certain FDA advisory  
 committees by the Commissioner of  
 Food and Drugs. The table in the  
 document contained several errors. This  
 document corrects those errors.

**FOR FURTHER INFORMATION CONTACT:** Lisa  
 Granger, Office of Policy, Food and Drug  
 Administration, 10903 New Hampshire  
 Ave., Bldg. 32, rm. 3330, Silver Spring,  
 MD 20993-0002, 301-796-9115.

**SUPPLEMENTARY INFORMATION:** In the  
**Federal Register** of Monday, August 25,  
 2014, in FR Doc. 2014-20017, on page  
 50659 the table is corrected to read:

Name of committee	Date of expiration
Advisory Committee for Pharmaceutical Science and Clinical Pharmacology .....	January 22, 2016.
Gastrointestinal Drugs Advisory Committee .....	March 3, 2016.
Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Reproductive Health Drugs Advisory Committee) .....	March 23, 2016.
Arthritis Advisory Committee .....	April 5, 2016.
Pharmacy Compounding Advisory Committee .....	April 25, 2016.
Anesthetic and Analgesic Drugs Advisory Committee .....	May 1, 2016.
Blood Products Advisory Committee .....	May 13, 2016.
Pulmonary-Allergy Drugs Advisory Committee .....	May 30, 2016.
Drug Safety and Risk Management Advisory Committee .....	May 31, 2016.
Science Advisory Board to the National Center for Toxicological Research .....	June 2, 2016.
Peripheral and Central Nervous System Drugs Advisory Committee .....	June 4, 2016.
Psychopharmacologic Drugs Advisory Committee .....	June 4, 2016.
Transmissible and Spongiform Encephalopathies Advisory Committee .....	June 9, 2016.
Science Board to the Food and Drug Administration .....	June 26, 2016.
Allergenic Products Advisory Committee .....	July 9, 2016.

Dated: September 3, 2014.

**Jill Hartzler Warner,**  
*Associate Commissioner for Special Medical  
 Programs.*

[FR Doc. 2014-21369 Filed 9-8-14; 8:45 am]

**BILLING CODE 4164-01-P**

**DEPARTMENT OF HEALTH AND  
 HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA-2014-N-1049]

**Exploring the Expansion of  
 Conditional Approval to Appropriate  
 Categories of New Animal Drugs**

**AGENCY:** Food and Drug Administration,  
 HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug  
 Administration (FDA) is announcing  
 that it is beginning the exploration  
 process described in a stated  
 performance goal in the Animal Drug  
 User Fee Amendments of 2013 (ADUFA  
 III) goals letter. Consistent with the  
 performance goal, the FDA is inviting  
 comments in regard to the Agency  
 exploring the use of statutory changes to  
 expand the use of conditional approval

beyond new animal drugs intended for minor species or for minor uses in major species to additional categories of new animal drugs as appropriate.

**DATES:** Although you can comment on this document at any time, to ensure that the Agency considers your comment before finalizing work on the exploration process described in this document, submit either electronic or written comments by March 9, 2015.

**ADDRESSES:** Submit electronic comments to <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** Matthew Lucia, Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rm. E444, Rockville, MD 20855, 240-402-0811, [matthew.lucia@fda.hhs.gov](mailto:matthew.lucia@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:**

### I. Background

FDA considers the timely review of the safety and effectiveness of new animal drugs to be central to the Agency's mission to protect and promote the public health. Before 2004, the timeliness and predictability of the new animal drug review program was a concern. The Animal Drug User Fee Act enacted in 2003 (Pub. L. 108-130; hereinafter referred to as "ADUFA I"), authorized FDA to collect user fees for 5 years—fiscal year (FY) 2004 to FY 2008—that were to be dedicated to expediting the review of new animal drug applications according to certain performance goals and to expand and modernize the new animal drug review program. The Agency agreed to meet a comprehensive set of performance goals established to show significant improvement in the timeliness and predictability of the new animal drug review process. The implementation of ADUFA I provided a significant funding increase that enabled FDA to increase the number of staff dedicated to the new animal drug application review process.

In 2008, before ADUFA I expired, Congress passed the Animal Drug User Fee Amendments of 2008 (Pub. L. 110-316; hereinafter referred to as "ADUFA II") which included an extension of ADUFA for an additional 5 years—FY 2009 to FY 2013. ADUFA II performance goals were established based on ADUFA I FY 2008 review timeframes. In addition, FDA provided program enhancements to reduce review

cycles and improve communications during reviews.

In 2013, before ADUFA II expired, Congress passed the Animal Drug User Fee Amendments of 2013 (Pub. L. 113-14; hereinafter referred to as ADUFA III), which was signed by the President on June 13, 2013. Like its predecessors, ADUFA III included its own comprehensive set of performance goals. One such goal, as stated in the ADUFA III goals letter, was: "Beginning in early FY 2014, the Agency agrees to explore, in concert with industry, the feasibility of pursuing statutory revisions, consistent with the Agency's mission to protect and promote the public health, that may expand the use of conditional approvals to other appropriate categories of new animal drug applications and develop recommendations by September 30, 2015."

The conditional approval provisions are found in section 571 of the Federal Food, Drug and Cosmetic Act (the FD&C Act). These provisions allow an applicant to market a new animal drug intended for a minor species or a minor use in a major species after the applicant has demonstrated that the drug is safe and can be manufactured according to standards applicable to approval of applications under section 512(b)(1) of the FD&C Act (21 U.S.C. 360b(b)(1)), but before meeting the full requirements for demonstrating effectiveness by providing "substantial evidence" that the drug is effective. Instead, the applicant seeking conditional approval must demonstrate a "reasonable expectation of effectiveness" and has up to 5 years to meet the requirements for demonstrating "substantial evidence" of effectiveness and receive complete approval of an application filed under section 512(b) of the FD&C Act.

Today, FDA is announcing that it is beginning the exploration process described in the ADUFA III goals letter. With this document, FDA is requesting comments in regard to the Agency exploring the use of statutory changes to expand the use of conditional approval to appropriate categories of new animal drugs beyond those intended for use either in minor species or for minor uses in major species. FDA is opening a public docket to receive comments on the issue. In particular, FDA is inviting comments on the following specific questions:

1. Which categories of new animal drugs, if any, beyond those intended for minor species or minor uses in major species, should be considered by FDA for conditional approval in accordance

with the current conditional approval process and why?

2. How would expanding conditional approval positively or negatively affect animal health?

FDA will be reviewing the docket and considering comments submitted as it moves forward with this process. The docket will remain open for 180 days following publication of this document in the **Federal Register**.

### II. Comments

Interested persons may submit electronic comments regarding this document to <http://www.regulations.gov> or written comments to the Division of Dockets Management (see **ADDRESSES**). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at <http://www.regulations.gov>.

Dated: September 2, 2014.

**Leslie Kux,**

*Assistant Commissioner for Policy.*

[FR Doc. 2014-21227 Filed 9-8-14; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2014-N-1050]

### Exploring the Feasibility of Pursuing Statutory Revisions and Other Modifications to Existing Procedures and Requirements Related to the Approval of Combination Drug Medicated Feeds

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that it is beginning the exploration process described in a stated performance goal in the Animal Drug User Fee Amendments of 2013 (ADUFA III) goals letter. Consistent with the performance goal, FDA is inviting comments in regard to the Agency exploring the use of statutory changes to modify the current requirement that the use of multiple new animal drugs in a combination drug medicated feed be the subject of an approved new animal drug application (NADA). The Agency also is inviting comment on potential changes to procedures and requirements related to the NADA approval process for such